Evidence map›Paper›PMID 35752680›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

Genetic landscape of early-onset dementia in Hungary.

Dora Csaban, Anett Illes, Toth-Bencsik Renata, Peter Balicza, Klara Pentelenyi, Viktor Molnar, Andras Gezsi, Zoltan Grosz, Aniko Gal, Tibor Kovacs and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Amyloid Precursor Protein and Alzheimer's Disease.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Dora CsabanInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, 1082, Budapest, Hungary.
Anett IllesPentaCore Laboratory Budapest, Budapest, Hungary.
Toth-Bencsik RenataInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, 1082, Budapest, Hungary.
Peter BaliczaInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, 1082, Budapest, Hungary.
Klara PentelenyiInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, 1082, Budapest, Hungary.
Viktor MolnarInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, 1082, Budapest, Hungary.
Andras GezsiDepartment of Measurement and Information Systems, Budapest University of Technology and Economics, Budapest, Hungary.
Zoltan GroszInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, 1082, Budapest, Hungary.
Aniko GalInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, 1082, Budapest, Hungary.
Tibor KovacsDepartment of Neurology, Semmelweis University, Budapest, Hungary.
Peter KlivenyiDepartment of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary.
Maria Judit MolnarInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, 1082, Budapest, Hungary. molnar.mariajudit@med.semmelweis-univ.hu.ORCID http://orcid.org/0000-0001-9350-1864
Semmelweis University · HUBudapest University of Technology and Economics · HUUniversity of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEarly-onset dementias (EOD) are predominantly genetically determined, but the underlying disease-causing alterations are often unknown. The most frequent forms of EODs are early-onset Alzheimer's disease (EOAD) and frontotemporal dementia (FTD). PATIENTS: This study included 120 Hungarian patients with EOD (48 familial and 72 sporadic) which had a diagnosis of EOAD (n = 49), FTD (n = 49), or atypical dementia (n = 22).

resultsMonogenic dementia was detected in 15.8% of the patients. A pathogenic hexanucleotide repeat expansion in the C9ORF72 gene was present in 6.7% of cases and disease-causing variants were detected in other known AD or FTD genes in 6.7% of cases (APP, PSEN1, PSEN2, GRN). A compound heterozygous alteration of the TREM2 gene was identified in one patient and heterozygous damaging variants in the CSF1R and PRNP genes were detected in two other cases. In two patients, the coexistence of several heterozygous damaging rare variants associated with neurodegeneration was detected (1.7%). The APOE genotype had a high odds ratio for both the APOE ɛ4/3 and the ɛ4/4 genotype (OR = 2.7 (95%CI = 1.3-5.9) and OR = 6.5 (95%CI = 1.4-29.2), respectively). In TREM2, SORL1, and ABCA7 genes, 5 different rare damaging variants were detected as genetic risk factors. These alterations were not present in the control group.

conclusionBased on our observations, a comprehensive, targeted panel of next-generation sequencing (NGS) testing investigating several neurodegeneration-associated genes may accelerate the path to achieve the proper genetic diagnosis since phenotypes are present on a spectrum. This can also reveal hidden correlations and overlaps in neurodegenerative diseases that would remain concealed in separated genetic testing.

Indexed as

Alzheimer DiseaseFrontotemporal DementiaApolipoproteins EHigh-Throughput Nucleotide SequencingHumansHungaryLDL-Receptor Related ProteinsMembrane Transport ProteinsMutationApolipoproteins ELDL-Receptor Related ProteinsMembrane Transport ProteinsSORL1 protein, humanAlzheimer’s diseaseEarly-onset dementiaFrontotemporal dementiaGenetic riskMonogenic formsNext-generation sequencing

Identifiers

PMID35752680
PMCPMC9385840
OpenAlexW4283463192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.